I n early april 2009, cases of human infection with 2009 pandemic influenza A (H1N1) virus were identified in the United States 1,2 and Mexico, 3 and the virus then spread rapidly to other regions of the world. 4, 5 The 2009 H1N1 virus is a triple-reassortant influenza virus containing genes from human, swine, and avian influenza viruses. [6] [7] [8] After documentation of human-to-human transmission of the virus in at least three countries in two of the six world regions defined by the World Health Organization (WHO), the WHO raised the pandemic level from 5 to 6, the highest level. 9 The first three cases of confirmed infection with the virus in China were documented between May 10 and May 15, 2009. 10 Since this was a new and potentially serious infectious disease, all patients with confirmed infection who had been hospitalized were quarantined in the hospital to isolate them from the general population. The hospital quarantine allowed us to closely monitor patients, tracking the incubation period of the disease, its clinical features, the results of laboratory and radiographic tests, and the nature and extent of viral shedding. This report describes the clinical and epidemiologic characteristics of the first 426 patients hospitalized in China from May to June 2009 with confirmed cases of 2009 pandemic influenza A (H1N1) virus infection.
Me thods

Data Sources
On May 7, 2009 , a national network was organized to monitor infection with the 2009 pandemic influenza A (H1N1) virus in China. The network included the Chinese Ministry of Health, the Chinese Center for Disease Control and Prevention, and all community and teaching hospitals in China. A national guideline, adapted from guidelines provided by the U.S. Centers for Disease Control and Prevention, was published on May 9 and used to direct the surveillance, reporting, diagnosis, and treatment of the disease. A suspected case was defined as an influenza-like illness (temperature ≥37.5°C and at least one of the following symptoms: sore throat, cough, rhinorrhea, or nasal congestion) and either a history of travel to a country where infection had been reported in the previous 7 days or an epidemiologic link to a person with confirmed or suspected infection in the previous 7 days. A confirmed case was defined by a positive result of a real-time reverse-transcriptasepolymerase-chain-reaction (RT-PCR) assay performed at a laboratory operated under the auspices of the Chinese Center for Disease Control and Prevention. A close contact was defined as a person who lived with or was exposed to the respiratory secretions or other bodily fluids of someone with suspected or confirmed infection.
Thermal scanners were installed at all airports and ports of entry to China. Persons suspected of being infected and persons identified as close contacts were quarantined for 7 days, during which time pharyngeal or nasopharyngeal swabs were collected for detection of the virus by means of a real-time RT-PCR assay. The average time between obtaining the samples and testing was 1 to 2 hours. There are 63 laboratories operated by the Chinese Center for Disease Control and Prevention across China, all of which are located in large cities. Persons with confirmed cases of infection were admitted to infectious diseases hospitals, where they could be quarantined.
The incubation period was defined as the time from exposure to the onset of illness. Patients were followed until discharge, with symptoms and signs recorded daily. The details of all investigations and treatments were recorded. Serial pharyngeal or nasopharyngeal swabs were analyzed daily for the presence of 2009 pandemic influenza A (H1N1) virus with the use of real-time RT-PCR testing. A return to normal body temperature was defined as a temperature of less than 37.3°C for 12 hours after the withdrawal of any antipyretic treatment. The criteria for discharge (as defined in the guideline) were two readings of normal body temperature taken on 2 consecutive days, the absence of respiratory symptoms, and negative results on the testing of samples from two consecutive pharyngeal or nasopharyngeal swabs.
Data collection and analysis were coordinated by the Chinese Ministry of Health. The medical records of patients discharged before June 30 were copied and sent to the data-collection center in Beijing. Data were reviewed by a trained team of physicians and medical students and entered in duplicate into a computerized database. Patient confidentiality was maintained by recording only the date of birth and sex on the data-collection form. The research ethics board at Beijing Ditan Hospital approved the study design. Approval by the institutional review boards at participating hospitals was not required because of the general acknowledgment that it was in the interest of the public health to collect data on an emerging pathogen.
Laboratory Confirmation of Infection
The 2009 H1N1 virus was detected with the use of a real-time RT-PCR assay in accordance with the protocol from the U.S. Centers for Disease Control and Prevention, as recommended by the WHO. 11 The PCR products were sequenced for further confirmation with the use of the BigDye Terminator, version 3.1 Cycle Sequencing Kit (Applied Biosystems) in accordance with the manufacturer's instructions.
Statistical Analysis
Continuous variables were summarized as means (±SD) or medians (with interquartile ranges). For categorical variables, the percentages of patients in each category were calculated. Clinical characteristics were compared between subgroups of patients with and those without fever and between patients with and those without a diagnosis of pneumonia with the use of an unpaired Student's t-test, chi-square test, or Fisher's exact test, as appropriate.
Multiple logistic-regression analysis was used to identify independent predictors of viral-shedding time among patients receiving treatment with oseltamivir. The outcome was predicted with the use of factors such as age, sex, severity or number of symptoms (e.g., fever, cough, sore throat, or cough with production of sputum), and the interval between symptom onset and initiation of oseltamivir therapy (less than or more than 48 hours). A P value of less than 0.05 was considered to indicate statistical significance. All analy- ses were carried out with the use of SPSS software for Windows (release 13.0).
R esult s
Demographic and Clinical Characteristics of the Patients
Sixty-one major hospitals located in 20 provinces across the country were involved in the emergency public health response. The first case of confirmed imported infection was identified on May 10, 2009 , and the first secondary case of confirmed infection (in a patient with known exposure to a person with imported infection) was identified on May 29. The first domestic case -in which the person infected had no clear history of exposure -was reported on June 13. On mainland China, there were 22 laboratory-confirmed cases in May and 544 such cases in June. By August 10, a total of 20,329 close contacts had been tested for 2009 virus infection had been found in the preceding 7 days. The category of Other included England (two patients), Indonesia (two), Korea (one), New Zealand (one), Greece (one), Israel (one), Yemen (one), and Venezuela (one). § Data on the incubation period were available for 125 patients who could clearly recall their exposure history. The incubation period was defined as the time from exposure to the onset of illness. ¶ Among the five patients who had adverse events, two were taking oseltamivir alone and three were taking oseltamivir plus levofloxacin or azithromycin. In the two patients with abnormal liver function, one was taking oseltamivir alone and one oseltamivir plus levofloxacin. In the two patients with nausea and vomiting, one was taking oseltamivir alone and one oseltamivir plus levofloxacin. The patient with a rash was taking oseltamivir and azithromycin. (Fig. 1) . (Demographic details, underlying medical conditions, and outcomes are listed in Table 1 .) The majority of the patients (81%) were Han Chinese, and 15.2% were white.
The median incubation period was 2 days (range, 1 to 7). As shown in Table 2 , 67.4% of patients had a fever. Less common symptoms included nausea, vomiting, and diarrhea. (A comparison of symptoms and duration of disease in patients with fever and those without fever is presented in Table 1 in the Supplementary Appendix, available with the full text of this article at NEJM.org.) Headache and lymphopenia were more common in patients with fever.
Laboratory and Radiographic Findings
Mild leukopenia was observed in 21.4% of 412 patients, and lymphopenia in 68.1% of adult patients and 92.3% of children (Table 3) . Data on the ratio of CD4 cells to CD8 cells were available for 212 patients, half of whom had an abnormal CD4:CD8 ratio (<1.4). Among the patients with leukopenia, the condition developed 2 days (range, 1 to 3) after the onset of illness, and white-cell counts returned to normal 7 days (range, 6 to 9) after the onset of illness. Abnormalities in chest radiography were detected in 19 of 273 patients on admission or after hospitalization. The most common features of these abnormalities appeared as local patchy shadowing on radiography (see Fig.  1 in the Supplementary Appendix). Diarrhea was more common in patients with pneumonia, but no significant variation in clinical features between patients with and those without pneumonia was found (see Table 2 in the Supplementary Appendix). Hypokalemia was present in 25.4% of the patients.
Clinical Outcomes
All 426 patients were discharged home. The median duration of fever was 3 days (range, 1 to 11). The median time from the onset of the first symptoms of illness to the first positive real-time RT-PCR test result for the virus was 1 day (range, 0 to 2). Treatment with oseltamivir was administered in a total of 351 patients and was administered to 254 of these patients (72.4%) within 48 hours after the onset of illness.
The results of serial virologic testing of samples from pharyngeal or nasopharyngeal swabs with the use of real-time RT-PCR were available for 421 patients. The median time from the onset of illness to a negative test result for real-time RT-PCR was 6 days (range, 1 to 17). The median interval from the time the temperature returned to normal to the time at which a negative test result was obtained was 3 days (with an interval of <1 day for 10.9% of patients; 1 to 2 days, 31.9%; 3 to 5 days, 45.0%; 6 to 7 days, 8.2%; and >7 days, 4.0%). In total, 96.0% of patients had a negative test result on real-time RT-PCR within a week after their temperature returned to normal. The results of a univariate analysis of the risk of persistent real-time RT-PCR positivity for the virus (>5 days) are shown in Table 3 in the Supplementary Appendix. Multivariable logistic-regression analysis showed that the following were independent risk factors for prolonged infection with the virus on the basis of real-time RT-PCR test results: an age of less than 14 years (odds ratio, 1.94; 95% confidence interval [CI], 1.13 to 3.31; P = 0.02), male sex (odds ratio, 1.69; 95% CI, 1.07 to 2.66; P = 0.02), and a period of more than 48 hours between the onset of disease and treatment with oseltamivir (odds ratio, 4.46; 95% CI, 2.58 to 7.72; P<0.001) ( Table 4) .
Adverse events occurred in five patients, two of whom were taking oseltamivir alone and three of whom were taking oseltamivir plus levofloxacin and azithromycin. Nausea and vomiting occurred in one patient taking oseltamivir alone and one patient taking oseltamivir plus levofloxacin, and oseltamivir was discontinued in both patients. Abnormal liver function (elevated levels of serum liver enzymes or bilirubin) occurred in one patient taking oseltamivir and one patient taking oseltamivir plus levofloxacin, and rash occurred in one patient taking oseltamivir plus azithromycin. All complications were mild and resolved spontaneously before discharge.
Discussion
We describe a cohort of 426 patients identified in 20 provinces in China who were hospitalized for 2009 pandemic influenza A (H1N1) virus infection between May and June 2009. The decision to undertake stringent quarantine and isolation measures regarding these patients was based on the unknown biologic action of the virus and the absence of effective vaccination. Since July 10, 2009, hospitalization for the purpose of isolation has not been mandated in China. Public health measures have instead focused on managing clusters of infection and complications of the illness in certain patients.
To date, it has been difficult to define the true incubation period of the virus. 6, [12] [13] [14] Analysis of 642 cases from the United States 6 suggested an incubation period of 2 to 7 days. Close observation of confirmed cases in China provided the opportunity to investigate the incubation period in 125 patients with an exact date of onset of illness. The median incubation period was 2 days, with a range of 1 to 7 days.
As compared with patients in the United States 6 and Japan 13 and those in Mexico and other countries, 14 fewer patients in our cohort (67.4%, vs. 94% in the United States) presented with fever. The incidence of nausea, vomiting, and diarrhea was also much lower than previously reported. In our cohort, 21.4% of 412 patients had leukopenia (white-cell count, <4000 per cubic millimeter), and 68.1% of adults and 92.3% of children had lymphopenia (total lymphocyte count, <1500 per cubic millimeter in adults and <3000 in children). None of the patients had thrombocytopenia (total platelet count, <100,000 per cubic millimeter). The lymphopenia was transient. Both leukocytosis and leukopenia were reported in hospitalized patients in California. 15 An abnormal ratio of CD4:CD8 cells (<1.4) was present in half of our patients. These transient alterations in the numbers of peripheral-blood leukocytes are similar to those seen in cases of seasonal influenza; Fas-Fas ligand signaling, which induces apoptosis, plays a major role in the mechanisms regulating the leukocyte population. 16 Hypokalemia was documented in 25.4% of our patients as compared with 43 to 90% of patients with severe acute respiratory syndrome (SARS) during hospitalization. 17, 18 The mechanism of hypokalemia is unknown.
Nineteen patients had abnormalities on chest radiography, but, unlike patients with the H1N1 virus in Mexico, 19 none had severe pneumonia. The viral infection in patients with pneumonia had no distinguishing epidemiologic, clinical, or laboratory features. However, the sample was small. Patients with pneumonia recovered quickly. This may be due in part to early laboratory diagnosis and early treatment with oseltamivir. With the use of real-time RT-PCR testing at both local branches and the laboratory at the Chinese National Influenza Center in Beijing, the Chinese Center for Disease Control and Prevention requires a median time of just 1 day from the onset of illness to confirm the diagnosis.
Of the 19 patients with pneumonia, 18 were given oseltamivir within 48 hours after the onset of illness. In Mexico, 19 the time between the onset of symptoms and admission to the hospital ranged from 4 to 25 days (median, 6), all patients had an influenza-like illness at presentation that progressed over a period of 5 to 7 days, none of the patients received oseltamivir before admission, and 11 began receiving oseltamivir 8 days after the onset of symptoms. According to the WHO guidelines on the pharmacologic management of influenza virus, patients who are at risk for pneumonia should be treated with oseltamivir or zanam ivir as soon as symptoms develop, if possible. 20 At present, however, the quality of the evidence supporting such recommendations is low. Observational studies of seasonal influenza have shown a reduction in progression to severe disease and hospitalization in patients treated with antiviral drugs, but additional randomized controlled trials are needed to evaluate the efficacy of these drugs in the treatment of both the seasonal flu and 2009 pandemic influenza A (H1N1) virus infection. The benefits of antiviral treatment should also be balanced against feasibility (i.e., the availability of the drug), the risk of resistance, and the cost to and demand on the health care system. Our study shows that the average duration of 2009 pandemic influenza A (H1N1) virus shedding, according to the results of PCR testing, is 6 days. Although a positive result of real-time RT-PCR testing does not necessarily indicate shedding of infective virus, PCR is more sensitive than culture for viral detection. 21 Using a positive result of real-time RT-PCR testing for 2009 pandemic influenza A (H1N1) virus infection within 5 days after symptom onset as a primary outcome, our study shows that beginning oseltamivir therapy within 48 hours after the onset of symptoms can reduce the duration of viral shedding (as measured by real-time RT-PCR assay). 22 The median interval from normalization of body temperature to a negative real-time RT-PCR test result was 3 days, with negative results obtained within 5 days for 87.9% of the study patients and within 7 days for 96.0%. This suggests that 96.0% of patients are no longer infectious and can return to work or school within a week after their temperature returns to normal. Our study has some limitations. First, the cases of infection in our patients are not clinically comparable with those in hospitalized patients in the United States or Mexico because of differences in hospitalization practices. Second, patients who became infected in their community and did not go to the hospital were not included in our study. Finally, although early treatment with oseltamivir did reduce the duration of viral shedding, the feasibility of its use, the risk of resistance, and the potential cost to and demand on the health care system remain concerns.
In conclusion, close observation of patients infected with the 2009 pandemic influenza A (H1N1) virus provided us with an accurate estimate of the incubation period and the duration of positive results of real-time RT-PCR testing. Late initiation of oseltamivir therapy (>48 hours after the onset of illness) was an independent risk factor for prolonged RT-PCR positivity.
